Oruka Therapeutics, Inc. (ORKA)

In January 2026, Oruka Therapeutics announced positive interim Phase 1 data for ORKA-002 and provided updates on ORKA-001 trials, also presenting at the 44th Annual J.P. Morgan Healthcare Conference. In December 2025, the company was expected to be added to the Nasdaq Biotechnology Index (NBI) and announced a new board member and a board transition. In November 2025, Oruka Therapeutics reported its third-quarter 2025 financial results, provided a corporate update, and presented at investor conferences. In September 2025, Oruka Therapeutics announced a $180 million private placement. In April 2024, ARCA biopharma and Oruka Therapeutics announced a definitive agreement to merge in an all-stock transaction, with the combined entity operating as Oruka Therapeutics.

The provided information does not contain details regarding demand seasonality for Oruka Therapeutics, Inc.'s products and services. Demand for its future products will likely be driven by disease prevalence and treatment efficacy rather than seasonal fluctuations.

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapeutics for chronic inflammatory and immune-mediated diseases, particularly psoriasis (PsO) and psoriatic arthritis (PsA). Their mission is to set a new standard for treating chronic skin conditions, aiming for high rates of complete disease clearance with infrequent dosing. The company's pipeline includes ORKA-001, an IL-23p19 inhibitor in Phase 1 trial; ORKA-002, an IL-17A and IL-17F inhibitor with positive Phase 1 data; ORKA-003, targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. The company utilizes a proprietary AI-driven drug discovery platform.

Oruka Therapeutics, Inc. is headquartered in Menlo Park, California, United States.

Oruka Therapeutics is building a positive reputation in the biotechnology and pharmaceutical sectors, particularly for chronic skin diseases. Positive Phase 1 data for ORKA-002, its expected inclusion in the Nasdaq Biotechnology Index, the merger with ARCA biopharma, and a $180 million private placement have contributed to its reputation. The company emphasizes its experienced team of drug developers and strategists.

Institutional ownership of Oruka Therapeutics stands at 93.23%, while insider ownership is 3.82%.